Skip to main content
Top

2009 | OriginalPaper | Hoofdstuk

21 Parkinson en Lewy-body-dementie (DLB)

Auteur : K.L. Leenders

Gepubliceerd in: Handboek dementie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Kernpunten

  • De klinische syndromen van het Parkinson Dementie Complex (PDD) en Lewybody- dementie (DLB) lijken veel op elkaar en zijn doorgaans alleen in het begin van het ziekteproces van elkaar te onderscheiden. De aan PDD en DLB ten grondslag liggende cerebrale pathologie lijkt eveneens sterk op elkaar. PDD en DLB samen worden thans erkend als een relatief vaak voorkomend en belangrijk klinisch probleem.
  • Het onderscheid tussen PDD en DLB is meer van belang in het kader van wetenschappelijk onderzoek dan voor de dagelijkse klinische praktijk.
  • In vergevorderde stadia kan het onderscheid met Alzheimer – voor zover het de dementie betreft – op klinische gronden moeilijk zijn.
  • De inzet van hulponderzoeken moet zorgvuldig geschieden.
  • Symptomatische behandelingen kunnen slechts in beperkte mate worden gegeven, maar zijn voor een aantal indicaties effectief. Curatieve behandeling is nog niet mogelijk.
Literatuur
go back to reference Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387-92. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387-92.
go back to reference Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633-7. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633-7.
go back to reference Bhasin M, Rowan E, Edwards K, et al. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry. 2007;22(9):890-5. Bhasin M, Rowan E, Edwards K, et al. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry. 2007;22(9):890-5.
go back to reference Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314-24. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314-24.
go back to reference Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509-18. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509-18.
go back to reference Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689-707. Quiz 1837. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689-707. Quiz 1837.
go back to reference Jellinger KA, Seppi K, Wenning GK, et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm. 2002;109(3):329-39. Jellinger KA, Seppi K, Wenning GK, et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm. 2002;109(3):329-39.
go back to reference Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812-9. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812-9.
go back to reference McKeith I, Mintzer J, Aarsland D, et al. International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol. 2004;3(1):19-28. McKeith I, Mintzer J, Aarsland D, et al. International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol. 2004;3(1):19-28.
go back to reference McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-72. McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-72.
go back to reference McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-24. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-24.
go back to reference McKeith IG. Dementia with Lewy bodies. Br J Psychiatry. 2002;180:144-7. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry. 2002;180:144-7.
go back to reference Mikhno A, Devanand D, Pelton G, et al. Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer’s disease. J Nucl Med. 2008;49(8):1262-9. Mikhno A, Devanand D, Pelton G, et al. Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer’s disease. J Nucl Med. 2008;49(8):1262-9.
go back to reference Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49(3):390-8. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49(3):390-8.
go back to reference Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol. 2006;59(2):298-309. Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol. 2006;59(2):298-309.
go back to reference Williams MM, Xiong C, Morris JC, et al. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935-41. Williams MM, Xiong C, Morris JC, et al. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935-41.
go back to reference Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164-73. Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164-73.
Metagegevens
Titel
21 Parkinson en Lewy-body-dementie (DLB)
Auteur
K.L. Leenders
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8061-9_21